View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 3, 2020

Roche’s Rozlytrek gets EC approval to treat solid tumours and NSCLC

Roche has received conditional marketing approval from the European Commission (EC) for Rozlytrek (entrectinib) to treat solid tumours in patients aged 12 years of age and above.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology